Menopause remedy sales
This article was originally published in The Tan Sheet
Executive Summary
Drugstore.com sales of supplements for menopause symptoms during third week of July jumped 47% over average weekly sales for the year, company says in first edition of the Health & Beauty Index. Increase followed release of Women's Health Initiative findings questioning safety of hormone replacement therapies, and supplement makers have since stepped up PR efforts touting their products as HRT alternatives (1"The Tan Sheet" July 29, 2002, In Brief). July sales on drugstore.com of GSK's Remifemin jumped 46% from June levels; other top-selling brands included J&J Personal Products' Healthy Woman, Pharmavite's Nature's Resource Soy Balance. E-tailer's new monthly index measures U.S. population trends, attitudes through health and wellness purchases...
You may also be interested in...
HRT vs. supplements
Dietary Supplement Education Alliance is spending "in the five figures" to develop video news release (VNR) promoting supplement ingredients as alternatives to hormone replacement therapy for menopausal symptoms. Slated for release in early to mid August, the VNR will be accessible by every TV station in U.S. for possible inclusion in local news health segments. Two- to three-minute feature will include interviews with two Los Angeles-based doctors. Supplement marketers also are stepping up PR efforts following studies raising concerns about safety of long-term HRT use. GlaxoSmithKline (Remifemin) reps are now calling on family practitioners as well as OB/GYNs. Novogen is alerting independent pharmacists about safety, efficacy of its Promensil supplement, while Rexall (Sundown Menopause Support) is planning additional in-store promotions that may reference articles on HRT studies...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.